WW beats by $0.41, misses on revs; reaffirms FY23 revs guidance
- Reports Q3 (Sep) earnings of $0.54 per share, $0.41 better than the FactSet Consensus of $0.13; revenues fell 14.0% year/year to $214.87 mln vs the $221.62 mln FactSet Consensus.
- End of Period Subscribers of 4.0 million.
- End of Period Subscribers in Q3 2023 were up 6.0% versus the prior year period, driven by the Digital business and the inclusion of 45 thousand Clinical Subscribers. Q3 2023 End of Period Digital Subscribers increased 7.8% versus the prior year period. Q3 2023 End of Period Workshops + Digital Subscribers decreased 7.3% versus the prior year period.
- Co reaffirms guidance for FY23, sees FY23 revs of $890-$910 mln vs. $900.84 mln FactSet Consensus.
- Operating income is now expected to be in the range of $31.0 million to $43.0 million, compared to the previously provided range of $39.0 million to $51.0 million, due to increased anticipated restructuring charges. Adjusted operating income, which excludes the net impact of restructuring charges and acquisition transaction costs, is still expected to be towards the high end of the previously provided range of $80.0 million to $85.0 million.
No comments:
Post a Comment